Aug. 28, 2008
Prescriber's Letter
Unbiased Evidence and Advice You Can Trust on New Developments in Drug Therapy 
 Prescriber's Practice Pearl from Prescriber's Letter

 Practice Pearl - September 2008

     A new code of conduct will change how companies market Rx meds.
     You'll see fewer pens, mugs, notepads, and other giveaways... and more limits on restaurant meals and promotional events.
     The new code is VOLUNTARY...self-imposed by the drug companies' own association, PhRMA. But most big drug companies will comply...to head off MANDATORY regulation.
     Expect your reps to follow these new rules:
     Gifts. Only educational items...textbooks, subscriptions, patient education materials, etc...worth up to $100...are okay.
     Meals. Modest meals along with education in your office or hospital will replace restaurant outings with reps.
     Educational talks. Drug companies can still sponsor CME and educational programs at restaurants, but the CME provider or organizer will make the arrangements...not the drug company.
     Drug samples. These are still okay. No new restrictions.
     Payments to prescribers. The federal gov't may soon require manufacturers to publicly report gifts and payments to physicians... under the pending Physician Payment Sunshine Act.
     Literature. Reps still CAN'T legally talk about off-label uses...but they CAN hand you reprints of scientifically valid articles...under certain conditions.
     Even some experts who are antimarketing see value in reps distributing good published literature about off-label uses.
     But beware.  Literature might be cherry-picked to emphasize desirable outcomes and omit studies that show no benefit or even harm.
     Expect to see more direct-to-consumer ads. They work.  About a third of adults ask for an advertised drug...and nearly half get it.
     NoFreeLunch.org, PrescriptionProject.org, and others are pushing legislation to rein in drug company influence.
     Keep in mind that Prescriber's Letter never takes advertising. If you want an objective analysis of a drug or therapy, ask us.  We'll send you our published analyses...or consider the subject for future research and publication.

View Detail-Document #240901
 What's a Detail Document?
 Learn more about Prescriber's Letter
 Subscribe to the entire Prescriber's Letter service
Copyright © 2008 Prescriber's Letter. Illegal to reproduce and/or forward.
PrescribersLetter.com

Click here to Subscribe Today!
Return to top
 Prescriber's Letter: September 2008; Vol: 15, No. 9
Return to top
Click here to Subscribe Today!

Prescriber's Letter is an independent service, providing unbiased information to subscribers, who are its sole means of support. No advertising of any kind is accepted.

Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments.

Our editors have thoroughly researched the information with input from experts, government agencies, and national organizations.

Information and Internet links in this article were current as of the date of publication.

 More for MDGrad Users
 Useful Links
  
Home | Search or Browse | Index of Topics | Privacy Policy | Email Us
Jeff M. Jellin, PharmD, Founding Editor
3120 W. March Lane, PO Box 8190, Stockton, CA 95208, Tel:(209) 472-2240 Fax:(209) 472-2249
Copyright © 1995-2008 Therapeutic Research Center, All rights reserved.